Document is current
Any future updates will be listed below
-
Authors
Tsuji, Hyuma https://orcid.org/0000-0001-5282-7366
Lin, Hsing-Yi
Kinoshita, Suguru
Jinguji, Hidemasa
Nakazawa, Yosuke https://orcid.org/0000-0002-3595-0896
Ogo, Masashi
Ohyama, Manabu https://orcid.org/0000-0002-2662-5717
- License Information
-
More Information
Article History
Received: 31 July 2025
Accepted: 20 October 2025
First Online: 17 November 2025
Declarations
:
: Ethical approval for the isolation of DSCC from human scalp tissue was granted by the human research ethics committees at the Shiseido Global Innovation Center, under the project titled "Evaluation of Hair Follicle Regeneration Ability of Cultured Cells Derived from Scalp Tissue," granted on 15 March 2023 (#18000030). All donors provided written informed consent prior to participation. The BM-MSC, AD-MSC, and PBMC, were purchased from Promocell and Precision for Medicine. Both companies have confirmed that ethical approval was obtained for the collection of human cells, and that donors provided informed consent. Promocell and Precision for Medicine outline their compliance with ethical and regulatory standards in their official documents (Promocell: , Precision for Medicine: ).
: Not applicable.
: M Ohyama has earned advisory fees from Taisho Pharmaceutical Co. and ROHTO Pharmaceutical Co. concerning this study topic, along with lecture and advisory fees for unrelated topics from Eli Lilly Co., Pfizer Inc., Sanofi KK., Kyowa Kirin Co., Maruho Co., Bristol-Myers Squibb Japan, and AbbVie GK. He has received research funding for this study topic from Shiseido Co, Ltd., and for unrelated topics from Maruho Co., Advantest Co., and Sun Pharma Japan Ltd. HT, HL, HJ, SK, YN, and M Ogo are employees of Shiseido Co, Ltd.
